Publications by authors named "Revathi Ananthakrishnan"

Claim this Profile
T
TITE-STEIN: Time-to-event simple toxicity and efficacy interval design to accelerate phase I/II trials.
Hao Sun, Jieqi Tu, Revathi Ananthakrishnan, Eunhee Kim

J Biopharm Stat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ensuring Quality and Interpretability of Progression Free Survival and Overall Survival in Oncology Clinical Trials.
Philip He, Haijun Ma, Chengxing Cindy Lu, Revathi Ananthakrishnan, Gu Mi

Ther Innov Regul Sci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncology.
Hao Sun, Hsin-Yu Lin, Jieqi Tu, Revathi Ananthakrishnan, Eunhee Kim

J Biopharm Stat· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective.
Daniel Li, Zhenzhen Xu, Shihua Wen, Revathi Ananthakrishnan, Yeonhee Kim

Ther Innov Regul Sci· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.
Daisuke Minakata, Tadao Ishida, Kiyoshi Ando, Rikio Suzuki, Junji Tanaka, Revathi Ananthakrishnan

Int J Hematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Shinichi Makita, Go Yamamoto, Dai Maruyama, Yuki Asano-Mori, Daisuke Kaji, Revathi Ananthakrishnan

Cancer Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An overview of the BOIN design and its current extensions for novel early-phase oncology trials.
Revathi Ananthakrishnan, Ruitao Lin, Chunsheng He, Yanping Chen, Daniel Li

Contemp Clin Trials Commun· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical review of oncology clinical trial design under non-proportional hazards.
Revathi Ananthakrishnan, Stephanie Green, Alessandro Previtali, Rong Liu, Daniel Li

Crit Rev Oncol Hematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy.
Revathi Ananthakrishnan, Stephanie Green, Daniel Li, Michael LaValley

Contemp Clin Trials Commun· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials.
Revathi Ananthakrishnan, Stephanie Green, Daniel Li, Michael LaValley

Contemp Clin Trials Commun· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.
Randeep Sangha, Andrew Davies, Nam H Dang, Michinori Ogura, David A MacDonald, Revathi Ananthakrishnan

J Drug Assess· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.
Daniel J DeAngelo, Wendy Stock, Anthony S Stein, Andrei Shustov, Michaela Liedtke, Revathi Ananthakrishnan

Blood Adv· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
Revathi Ananthakrishnan, Stephanie Green, Mark Chang, Gheorghe Doros, Joseph Massaro

Contemp Clin Trials Commun· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Andrew Davies, Michael Crump, Revathi Ananthakrishnan

Clin Cancer Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
Andre Goy, Andres Forero, Nina Wagner-Johnston, W Christopher Ehmann, Michaela Tsai, Revathi Ananthakrishnan

Br J Haematol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Leena Gandhi, Rastislav Bahleda, Sara M Tolaney, Eunice L Kwak, James M Cleary, Revathi Ananthakrishnan

J Clin Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of oncology clinical trials: a review.
Revathi Ananthakrishnan, Sandeep Menon

Crit Rev Oncol Hematol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration of cell biology, pharmacological modeling and statistical analysis: part I: cell biology and PK/PD in the Oncology paradigm.
Revathi Ananthakrishnan, Sandeep Menon

Crit Rev Oncol Hematol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.
Birgit Geoerger, Mark W Kieran, Stephan Grupp, Danuta Perek, Jill Clancy, Revathi Ananthakrishnan

Eur J Cancer· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
Sheri L Spunt, Stephan A Grupp, Terry A Vik, Victor M Santana, David J Greenblatt, Revathi Ananthakrishnan

J Clin Oncol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A mitotic kinesin-6, Pav-KLP, mediates interdependent cortical reorganization and spindle dynamics in Drosophila embryos.
Patrizia Sommi, Revathi Ananthakrishnan, Dhanya K Cheerambathur, Mijung Kwon, Sandra Morales-Mulia

J Cell Sci· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
Lecia V Sequist, Benjamin Besse, Thomas J Lynch, Vincent A Miller, Kwok K Wong, Revathi Ananthakrishnan

J Clin Oncol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The forces behind cell movement.
Revathi Ananthakrishnan, Allen Ehrlicher

Int J Biol Sci· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying the contribution of actin networks to the elastic strength of fibroblasts.
Revathi Ananthakrishnan, Jochen Guck, Falk Wottawah, Stefan Schinkinger, Bryan Lincoln

J Theor Biol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weak force stalls protrusion at the leading edge of the lamellipodium.
Sophie Bohnet, Revathi Ananthakrishnan, Alex Mogilner, Jean-Jacques Meister, Alexander B Verkhovsky

Biophys J· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis